http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#Head
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#assertion
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#provenance
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#pubinfo
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#assertion
http://purl.obolibrary.org/obo/DOID_8534
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_8534
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00448
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#association
http://www.w3.org/2000/01/rdf-schema#label
lansoprazole delayed release orally disintegrating tablets are a proton pump inhibitor ppi indicated for the treatment of active duodenal ulcer in adults 1 1 eradication of h pylori 1 2 maintenance of healed duodenal ulcers in adults 1 3 treatment of active benign gastric ulcer in adults 1 4 healing of non steroidal anti inflammatory drugs nsaid associated gastric ulcer in adults 1 5 risk reduction of nsaid associated gastric ulcer in adults 1 6 treatment of symptomatic gastroesophageal reflux disease gerd in adults and pediatric patients 1 year of age and older 1 7 treatment of erosive esophagitis ee in adults and pediatric patients 1 year of age and older 1 8 maintenance of healing of ee in adults 1 9 pathological hypersecretory conditions including zollinger ellison syndrome zes in adults 1 1 lansoprazole delayed release orally disintegrating tablets are indicated in adults for short term treatment for four weeks for healing and symptom relief of active duodenal ulcer see clinical studies 14 1 triple therapy lansoprazole delayed release orally disintegrating tablets amoxicillin clarithromycin lansoprazole delayed release orally disintegrating tablets in combination with amoxicillin plus clarithromycin as triple therapy is indicated in adults for the treatment of patients with h pylori h pylori h pylori see clinical studies 14 2 please refer to the full prescribing information for amoxicillin and clarithromycin dual therapy lansoprazole delayed release orally disintegrating tablets amoxicillin lansoprazole delayed release orally disintegrating tablets in combination with amoxicillin as dual therapy is indicated in adults for the treatment of patients with h pylori who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected microbiology h pylori see clinical studies 14 2 please refer to the full prescribing information for amoxicillin lansoprazole delayed release orally disintegrating tablets are indicated in adults to maintain healing of duodenal ulcers controlled studies do not extend beyond 12 months see clinical studies 14 3 lansoprazole delayed release orally disintegrating tablets are indicated in adults for short term treatment up to eight weeks for healing and symptom relief of active benign gastric ulcer see clinical studies 14 4 lansoprazole delayed release orally disintegrating tablets are indicated in adults for the treatment of nsaid associated gastric ulcer in patients who continue nsaid use controlled studies did not extend beyond eight weeks see clinical studies 14 5 lansoprazole delayed release orally disintegrating tablets are indicated in adults for reducing the risk of nsaid associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an nsaid controlled studies did not extend beyond 12 weeks see clinical studies 14 6 lansoprazole delayed release orally disintegrating tablets are indicated for short term treatment in adults and pediatric patients 12 to 17 years of age up to eight weeks and pediatric patients one to 11 years of age up to 12 weeks for the treatment of heartburn and other symptoms associated with gerd see clinical studies 14 7 lansoprazole delayed release orally disintegrating tablets are indicated for short term treatment in adults and pediatric patients 12 to 17 years of age up to eight weeks and pediatric patients one to 11 years of age up to 12 weeks for healing and symptom relief of all grades of ee for adults who do not heal with lansoprazole delayed release orally disintegrating tablets for eight weeks 5 to 1 it may be helpful to give an additional eight weeks of treatment if there is a recurrence of erosive esophagitis an additional eight week course of lansoprazole delayed release orally disintegrating tablets may be considered see clinical studies 14 8 lansoprazole delayed release orally disintegrating tablets are indicated in adults to maintain healing of ee controlled studies did not extend beyond 12 months see clinical studies 14 9 lansoprazole delayed release orally disintegrating tablets are indicated in adults for the long term treatment of pathological hypersecretory conditions including zollinger ellison syndrome see clinical studies 14 1
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB00448
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#provenance
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#pubinfo
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#sig
http://purl.org/nanopub/x/hasSignature
aaaO0hWMRrRWeBK6djicIgwpzZt+RhCRYA8UoswRrqobszcBB5tccaT9zS+i+AxFnRQsyI/qxxcd3+IuRSWuFSwYV87GgbxSk653LBZBVWCkm2YAETEQU6G43A3YZC71iAJ19CXPwUexvlNSY28XtPtgiRGI/1hT8pCnQZbeD5c=
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs
http://purl.org/dc/terms/created
2021-07-03T12:37:33.360+02:00
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RANH4LPzC_go2JhIclAfv_5pcgZwugffofMfMGXqhmczs
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs